Michigan Technology News and Entrepreneurs
Esperion Secures $50 Million To Finance Sales Expansion To Asia, Middle East
ANN ARBOR—Esperion Therapeutics, developers of a novel class of cholesterol-reducing drugs, announced that an investor group led by New York City-based Oberland Capital Management LLC agreed to provide the third and final tranche of funding under the revenue-based funding agreement totaling $50 million. The remaining funds are being released sooner than expected and in parallel








